Long-term efficacy and safety of eslicarbazepine acetate: Results of a 1-year open-label extension study in partial-onset seizures in adults with epilepsy-Reference-Cited by-同舟云学术

Long-term efficacy and safety of eslicarbazepine acetate: Results of a 1-year open-label extension study in partial-onset seizures in adults with epilepsy

Published:2010-07-16 Issue:10 Volume:51 Page:1963-1969
ISSN:0013-9580
Container-title:Epilepsia
language:en
Short-container-title:

Author:

Halász Peter,Cramer Joyce A.,Hodoba Danilo,Członkowska Anna,Guekht Alla,Maia Joana,Elger Christian,Almeida Luis,Soares-da-Silva Patricio,

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1528-1167.2010.02660.x/fullpdf

Reference16 articles.

1. Eslicarbazepine acetate (BIA 2-093);Almeida;Neurotherapeutics,2007

2. Eslicarbazepine Acetate

3. Enhanced expression of a specific hyperpolarization-activated cyclic nucleotide-gated cation channel (HCN) in surviving dentate gyrus granule cells of human and experimental epileptic hippocampus;Bender;J Neurosci,2003

4. Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives;Benes;J Med Chem,1999

5. Efficacy and safety of eslicarbazepine acetate (ESL) as add-on treatment in adults with refractory partial-onset seizures: BIA-2093-302 study;Ben-Menachem;Epilepsia,2008

Cited by 90 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term quality of life in patients with focal seizures treated with adjunctive eslicarbazepine acetate;Epilepsy & Behavior;2023-11

2. Real-world analysis of retention on cenobamate in patients with epilepsy in the United States;Epilepsy Research;2023-11

3. Efficacy and Safety of Eslicarbazepine Acetate: A Single-Center Experience;Epilia: Epilepsy and Community;2023-09-30

4. Cost‐effectiveness of cenobamate for focal seizures in people with drug‐resistant epilepsy;Epilepsia;2023-02-14

5. Time to baseline seizure count in patients with focal seizures receiving adjunctive eslicarbazepine acetate in a phase IV clinical trial;Clinical Neurology and Neurosurgery;2023-02